Literature DB >> 33825966

Coming Soon: The First-Ever Drug(s) for Refractory Chronic Cough.

Peter V Dicpinigaitis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33825966     DOI： 10.1007/s00408-021-00438-6

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


× No keyword cloud information.
  2 in total

1.  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

Authors:  Jaclyn A Smith; Michael M Kitt; Alyn H Morice; Surinder S Birring; Lorcan P McGarvey; Mandel R Sher; Yu-Ping Li; Wen-Chi Wu; Zhi Jin Xu; David R Muccino; Anthony P Ford
Journal:  Lancet Respir Med       Date:  2020-02-25       Impact factor: 30.700

2.  ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.

Authors:  Alyn H Morice; Eva Millqvist; Kristina Bieksiene; Surinder S Birring; Peter Dicpinigaitis; Christian Domingo Ribas; Michele Hilton Boon; Ahmad Kantar; Kefang Lai; Lorcan McGarvey; David Rigau; Imran Satia; Jacky Smith; Woo-Jung Song; Thomy Tonia; Jan W K van den Berg; Mirjam J G van Manen; Angela Zacharasiewicz
Journal:  Eur Respir J       Date:  2020-01-02       Impact factor: 16.671
  2 in total
  3 in total

1.  P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough.

Authors:  Wen-Wen Cui; Si-Yu Wang; Yu-Qing Zhang; Yao Wang; Ying-Zhe Fan; Chang-Run Guo; Xing-Hua Li; Yun-Tao Lei; Wen-Hui Wang; Xiao-Na Yang; Motoyuki Hattori; Chang-Zhu Li; Jin Wang; Ye Yu
Journal:  Comput Struct Biotechnol J       Date:  2022-03-31       Impact factor: 6.155

2.  LUNG Year in Review: 2021.

Authors:  Peter V Dicpinigaitis
Journal:  Lung       Date:  2022-01-18       Impact factor: 3.777

Review 3.  Recommended tool compounds and drugs for blocking P2X and P2Y receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Purinergic Signal       Date:  2021-09-02       Impact factor: 3.765
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.